Amounts within experiments
GHK-Cu study doses and delivery routes
A concentration in culture medium, a topical preparation and copper retained in skin answer different questions. None supplies an approved human GHK-Cu dose.
Culture concentrations
In the human fibroblast collagen experiment, stimulation began between 10^-12 and 10^-11 M and was greatest at 10^-9 M. M describes molar concentration in the cells' medium. The observation was increased collagen synthesis with unchanged cell numbers.
The minute culture concentrations impress me. Calculating exposure in living skin or throughout a person's body requires much more information. The preparation, route and measured endpoint are needed to understand the figure. GHK-Cu has no approved human dose by any route.
Topical preparations in human studies
The clinical and formulation literature describes creams, serums and gels with approximately 0.05% to 2% GHK-Cu by weight. That range describes studied formulations. It supplies no personal regimen.
The 45-man hair trial tested 50 mg/mL and 100 mg/mL of a complex containing 5-aminolevulinic acid and GHK. Its concentrations concern that combination. Attributing the full concentration or its hair-count outcome to GHK-Cu alone would misdescribe the experiment. The topical-delivery review discusses formulation strategies because delivery through the skin remains a central difficulty.
Excised-skin copper measurements
The skin-layer penetration experiment used excised human skin. In dermatomed skin, over 48 hours, 136.2 ± 17.5 micrograms/cm² of copper permeated and 97 ± 6.6 micrograms/cm² was retained. The permeability coefficient was 2.43 ± 0.51 × 10^-4 cm/h. The measured substance was copper applied as the tripeptide complex.
These are useful local measurements in a particular experimental skin preparation. They do not show intact GHK-Cu circulating through a volunteer or describe the fate of an injection. Quoting retention as the time a peptide lasts in the human body obscures the actual measurement.

Human systemic measurements
A rat study using chromatography documented rapid metabolism of free GHK to the shorter peptide HK after intravenous administration. Validated human measurements of systemic GHK-Cu half-life, bioavailability and tissue distribution remain absent.
I draw no human interval or injectable amount from that rat finding. A useful future human investigation would measure exposure alongside outcomes and adverse effects. Until then, a figure describing a cell dish or a skin chamber leaves the systemic question unanswered.